The effect of bumetanide on photodynamic therapy-induced peri-tumor edema of C6 glioma xenografts.
OBJECTIVE
The aim of this study was to investigate the effect of bumetanide on peri-tumor edema caused by photodynamic therapy (PDT) of intraparenchymal C6 glioma xenografts.


METHODS
Seven days after inoculation with C6 cells, rats with MRI-confirmed glioma received hematoporphyrin monomethyl ether (HMME)-mediated PDT, injection of bumetanide or a combination of the two treatments. After treatment, tumor volume, tumor weight, brain water content, microvessel density, expression of NKCC-1, Zonula occludens-1 (ZO-1), and animal survival time were examined.


RESULTS
In the PDT group, tumor growth was significantly inhibited and survival prolonged. Bumetanide enhanced the efficacy of PDT and reduced PDT-induced peri-tumor edema in the combined PDT + bumetanide treatment group where NKCC-1 expression in response to PDT was significantly suppressed. ZO-1 expression was significantly suppressed in the PDT-only group. This suppression was not observed in the combined PDT + bumetanide treatment group.


CONCLUSIONS
PDT, in combination with bumetanide was seen to significantly inhibit the growth of C6 glioma, relieve peri-tumor edema caused by PDT alone and prolong survival. These results suggest that PDT, in combination with bumetanide, may be a useful and promising strategy in the treatment of human glioma.
Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Xufeng
X
Zhang
Damin
D
Cong
Dawei
D
Shen
Xin
X
Gao
Lei
L
Chen
Shaoshan
S
Hu
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy*; D002034:Bumetanide / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D004232:Diuretics / Q000627:therapeutic use*; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005910:Glioma / Q000188:drug therapy*; D006415:Hematoporphyrins / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014183:Transplantation, Heterologous; D016896:Treatment Outcome
D015415:Biomarkers; D004232:Diuretics; D006415:Hematoporphyrins; D017319:Photosensitizing Agents; C494379:hematoporphyrin monomethyl ether; D002034:Bumetanide
NKCC-1; Zonula occludens-1 (ZO-1); bumetanide; hematoporphyrin monomethyl ether; microvessel density; peri-tumor edema; photodynamic therapy